Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …

Molecular changes in malignant tissue can lead to an increase in the expression levels of
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …

Cancer remains the leading cause of death worldwide despite advances in treatment
options for patients. As such, safe and effective therapeutics are required. Short peptides …

This paper discusses the role of peptides in cancer therapy with special emphasis on
peptide drugs which are already approved and those in clinical trials. The potential of …

Interest in the use of radionuclides for treatment of various diseases has a long history and
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …

Somatostatin receptor imaging (SRI) with [111 In-DTPA 0] octreotide has proven its role in
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs) …

Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that
originate from endocrine glands such as the pituitary, the parathyroids, and the …

Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in the
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer …

Somatostatins—also known as somatotropin-release inhibiting factors (SRIFs)—are a family
of cyclopeptides that have broad inhibitory effects on the secretion of hormones such as …

The organs at risk in radionuclide therapy with 177Lu-octreotate are the bone marrow and
the kidneys. The primary aim of this study was to develop an individualized dosimetry …